title: Zinplava Tackles Toxins Of Hard-to-Treat C. Difficile.
abstract: Merck has recently received FDA approval for bezlotoxumab (Zinplava), as a treatment to reduce recurrence of C. diffcile in patients 18 years of age or older who are receiving antibiotic treatment for the infection and for whom there is a high risk of recurrence.
authors.forename: Thomas
authors.initials: T
authors.lastname: Morrow
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000494:pharmacology*; D057134:Antibodies, Neutralizing / Q000191:economics* / Q000494:pharmacology*; D000080908:Broadly Neutralizing Antibodies; D016360:Clostridioides difficile / Q000187:drug effects*; D003015:Clostridium Infections / Q000188:drug therapy*; D006801:Humans; D055502:Secondary Prevention
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D000080908:Broadly Neutralizing Antibodies; C000613978:bezlotoxumab